Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVA: Rivaroxaban or Ticagrelor vs Clopidogrel in Intracranial Vascular Atherostenosis
NCT05047172Phase 3Active, not recruiting
- Sponsor
- University of Florida
- Start
- Aug 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban, ticagrelor in intracranial atherosclerosis (ICAD), stroke, sponsored by University of Florida. Started Aug 2022; status: active, not recruiting.
02
Drugs
rivaroxabanticagrelor
03
Conditions
intracranial atherosclerosis (ICAD)stroke
Beyond the preview
Go deeper on NCT05047172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047172.